Novartis is going after a $5 billion market with a new treatment for vision loss. That's a big threat to Regeneron

  • 📰 BusinessInsider
  • ⏱ Reading Time:
  • 1 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 4%
  • Publisher: 51%

日本 ニュース ニュース

日本 最新ニュース,日本 見出し

Novartis' drug brolucizumab just showed that it wasn't any worse than Eylea, a drug from Regeneron, at treating an eye disease.

このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む:

 /  🏆 729. in JP
 

コメントありがとうございます。コメントは審査後に公開されます。

日本 最新ニュース, 日本 見出し

Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。

J&J announces $5 billion share buyback program after report wipes out $50 billion in market valueJohnson & Johnson plans to repurchase $5 billion in shares after the company lost more than $50 billion in market value over two trading days following a scathing news report Friday claiming J&J knew its talc baby powders contained asbestos. Using the money from remorseless trump and remorseless Republicans they gave corporations in 2016 tax scam ! Asbestos isn't safe though. 1/7 men experience prostate in their lifetimes. This product has been around like 47 years. The uptick of prostate cancer correlates. They've lied about asbestos in the talcum. We will never know the disastrous effects this has caused the world. Scrambling to boost the share price of their executive stock options. What a wise use of R&D capital.
ソース: CNBC - 🏆 12. / 72 続きを読む »

Art market faces big test as $2 billion worth of artwork goes up for auctionIt is the biggest auction week of the year, and the biggest test for the art market. Check out the paintings expected to sell for tens of millions of dollars apiece, some of which could set records. 🤮🤮🤮
ソース: CNBC - 🏆 12. / 72 続きを読む »